Krystal Biotech Inc (KRYS)
Activity ratios
Short-term
Turnover ratios
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 8.87 | 13.82 | 18.08 | 83.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | 2.20 | 1.35 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | 18.26 | 23.36 | 21.98 | 20.61 | 20.35 | 19.04 | 11.39 | 5.99 | 5.75 | 4.64 | 6.61 | 20.91 | 10.83 | 6.52 | 4.70 | 5.61 | 11.65 | 6.36 | 4.57 | 5.78 |
| Working capital turnover | 0.18 | 0.10 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
The inventory turnover ratio for Krystal Biotech Inc has fluctuated over the periods provided, ranging from 8.87 to 83.31. This indicates that the company is managing its inventory efficiently, with higher turnover ratios suggesting that inventory is being sold more quickly. However, the significant variations in this ratio may warrant further investigation into changes in the company's inventory management practices.
In terms of receivables turnover, the company experienced a varying trend from 1.01 to 2.20 over the periods provided. A higher receivables turnover ratio indicates that the company is collecting its receivables more efficiently. The fluctuations in this ratio may indicate changes in the company's credit policies or the quality of its customers.
The payables turnover ratio for Krystal Biotech Inc ranged from 4.57 to 23.36 over the periods provided. A higher payables turnover ratio suggests that the company is paying its suppliers more quickly. The fluctuations in this ratio may reflect changes in the company's payment terms or supplier relationships.
The working capital turnover ratio for the company remained very low, ranging from 0.00 to 0.18 over the periods provided. This suggests that the company is not utilizing its working capital effectively to generate revenue. Further analysis may be needed to understand why the company's working capital turnover is so low and how it can be improved.
Overall, analyzing these activity ratios provides insight into Krystal Biotech Inc's efficiency in managing its inventory, receivables, payables, and working capital. Further investigation into the factors influencing these ratios can help identify areas for improvement in the company's operational efficiency and financial performance.
Average number of days
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 41.17 | 26.41 | 20.19 | 4.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Days of sales outstanding (DSO) | days | 165.91 | 271.24 | 363.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | 19.99 | 15.62 | 16.60 | 17.71 | 17.94 | 19.17 | 32.05 | 60.98 | 63.51 | 78.72 | 55.22 | 17.45 | 33.70 | 55.96 | 77.69 | 65.05 | 31.33 | 57.43 | 79.95 | 63.10 |
Days of inventory on hand (DOH) for Krystal Biotech Inc have been fluctuating over the past quarters, ranging from 4.38 days to 41.17 days. A decreasing trend in DOH indicates the company is managing its inventory efficiently, while an increasing trend could suggest potential issues with inventory management.
Days of sales outstanding (DSO) have also varied significantly, with values ranging from 165.91 days to 363.09 days. A higher DSO indicates a longer average collection period for accounts receivable, potentially impacting cash flow and liquidity.
The number of days of payables has shown some volatility, moving between 15.62 days to 79.95 days. Longer payables turnover could suggest favorable credit terms with suppliers but may also indicate potential liquidity challenges if payables are extended too far.
Overall, monitoring these activity ratios is crucial for evaluating Krystal Biotech Inc's operational efficiency, inventory management, accounts receivable collection, and supplier payment practices.
Long-term
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | 0.64 | 0.35 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.13 | 0.20 | 0.25 |
| Total asset turnover | 0.12 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Krystal Biotech Inc's long-term activity ratios paint a concerning picture of the company's efficiency in utilizing its fixed assets and total assets to generate revenue. The fixed asset turnover ratio has been very low and inconsistent over the periods, with a significant improvement from 0.00 in previous quarters to 0.64 in March 2024. This indicates that historically, the company has struggled to generate sales relative to its investment in fixed assets, but there has been a recent improvement in this aspect.
On the other hand, the total asset turnover ratio shows a similar trend of inefficiency in utilizing assets to generate sales. The ratio has been consistently low, which means that the company has not been effectively generating revenue in comparison to its total asset base. This could indicate issues with sales volume or asset utilization efficiency.
Overall, the low and inconsistent long-term activity ratios suggest that Krystal Biotech Inc may need to focus on improving its asset utilization strategies and operational efficiency to enhance its overall financial performance and profitability. Further analysis and investigation into the underlying factors contributing to these ratios would be necessary to provide a more comprehensive assessment of the company's operational effectiveness.